News | May 06, 2023
Ajanta pharma posts Q4FY23 consolidated PAT at Rs. 122.25 Cr
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
Organ Transplants triple across the country; rise from 5000 (2013) to more than 15000 in 2022
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Allianz is ISO 9001:2015 certified and INVIMA certified for storage, sampling, dispensation, and distribution of APIs to the Colombian market
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Subscribe To Our Newsletter & Stay Updated
